These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29223956)

  • 41. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased large VLDL and small LDL particles are related to lower bilirubin in Type 2 diabetes mellitus.
    Dullaart RP; de Vries R; Lefrandt JD
    Clin Biochem; 2014 Nov; 47(16-17):170-5. PubMed ID: 25149194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.
    Akinkuolie AO; Glynn RJ; Padmanabhan L; Ridker PM; Mora S
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27413042
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
    Boekholdt SM; Hovingh GK; Mora S; Arsenault BJ; Amarenco P; Pedersen TR; LaRosa JC; Waters DD; DeMicco DA; Simes RJ; Keech AC; Colquhoun D; Hitman GA; Betteridge DJ; Clearfield MB; Downs JR; Colhoun HM; Gotto AM; Ridker PM; Grundy SM; Kastelein JJ
    J Am Coll Cardiol; 2014 Aug; 64(5):485-94. PubMed ID: 25082583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
    Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
    Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals.
    Balling M; Langsted A; Afzal S; Varbo A; Davey Smith G; Nordestgaard BG
    Atherosclerosis; 2019 Jul; 286():97-104. PubMed ID: 31108411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.
    Festa A; Williams K; Hanley AJ; Otvos JD; Goff DC; Wagenknecht LE; Haffner SM
    Circulation; 2005 Jun; 111(25):3465-72. PubMed ID: 15983261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.
    Soedamah-Muthu SS; Chang YF; Otvos J; Evans RW; Orchard TJ;
    Diabetologia; 2003 May; 46(5):674-82. PubMed ID: 12743701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population.
    Hisamatsu T; Fujiyoshi A; Miura K; Ohkubo T; Kadota A; Kadowaki S; Kadowaki T; Yamamoto T; Miyagawa N; Zaid M; Torii S; Takashima N; Murakami Y; Okamura T; Horie M; Ueshima H;
    Atherosclerosis; 2014 Oct; 236(2):237-43. PubMed ID: 25105580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study.
    Mackey RH; Kuller LH; Sutton-Tyrrell K; Evans RW; Holubkov R; Matthews KA
    Am J Cardiol; 2002 Oct; 90(8A):71i-76i. PubMed ID: 12419483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk.
    Damasceno NR; Sala-Vila A; Cofán M; Pérez-Heras AM; Fitó M; Ruiz-Gutiérrez V; Martínez-González MÁ; Corella D; Arós F; Estruch R; Ros E
    Atherosclerosis; 2013 Oct; 230(2):347-53. PubMed ID: 24075767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis.
    Al-Shahrouri HZ; Ramirez P; Fanti P; Abboud H; Lorenzo C; Haffner S
    Clin Nephrol; 2010 Mar; 73(3):180-9. PubMed ID: 20178716
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
    Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Am J Cardiol; 2016 May; 117(9):1444-8. PubMed ID: 26969416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article).
    Hyun MH; Jang JW; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Medicine (Baltimore); 2019 Dec; 98(51):e18510. PubMed ID: 31861037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry.
    Navar AM; Wang TY; Li S; Robinson JG; Goldberg AC; Virani S; Roger VL; Wilson PWF; Elassal J; Lee LV; Peterson ED
    Am Heart J; 2017 Nov; 193():84-92. PubMed ID: 29129260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database.
    Karlson BW; Palmer MK; Nicholls SJ; Barter PJ; Lundman P
    Atherosclerosis; 2017 Oct; 265():54-59. PubMed ID: 28863328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.